DASH vs LCTX · P/E 76, rev $13.72B vs rev $9.5M
DoorDash, Inc. Class A Common Stock (DASH) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the DASH and LCTX stock pages for the full models.
Not investment advice.